Overview

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Status:
Not yet recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a randomised, double-blind, intravenous single-dose, four-arm parallel study designed to compare the PK of HLX11 and US, EU, and CN-sourced Perjeta® in healthy Chinese adult male subjects, and to assess the safety, tolerability, and immunogenicity of these 4 drugs.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Pertuzumab